Surrozen
PublicSurrozen is now publicly traded
The data on this page reflects Surrozen's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Mar 24, 2025
Total Funding Raised
$442M
Company Overview
Surrozen is a biotechnology company that discovers and develops antibody therapeutics targeting the Wnt pathway to promote tissue repair and regeneration across various organs and tissues.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Surrozen Comparables
Compare Surrozen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuvasq Biotechnologies | 77% | |
| RevOpsis Therapeutics | 75% | |
| Ceramedix, Inc. | 67% |
For institutional investors. Book with your work email.
Surrozen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Mar 24, 2025 | ||||
| Private Placement | Apr 1, 2024 | ||||
| PIPE | Aug 11, 2021 | ||||
| Series C | Jun 19, 2020 | ||||
| Series B | Mar 14, 2019 | ||||
Series A | Feb 15, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Surrozen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | PIPE, Series C, Private Placement, Series B, Series A |
| Horizons Ventures | Series B, Series C |
| StemPoint Capital LP | Private Placement |
| RA Capital Management | Private Placement |
| Braidwell | Private Placement |
| 5AM Ventures | Private Placement |
| The Chernin Group | Private Placement, Series C, Series A, Series B |
For institutional investors. Book with your work email.
Surrozen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.